Zydus Therapeutics reports positive topline results from EPICS-III Phase 2(b)/3 Trial of…
The trial met its primary composite endpoint, with a treatment difference in achieving a biochemical response of 48.5 per cent,…
Recover your password.
A password will be e-mailed to you.
- Advertisement -
- Advertisement -
Recover your password.
A password will be e-mailed to you.